CDH1 rs121912577: Hereditary Cancer Predisposition Explained
The genetic variant rs121912577 is a rare sequence change in the CDH1 gene on chromosome 16. In clinical literature, pathogenic alterations at this locus are linked to Hereditary Diffuse Gastric Cancer (HDGC) and lobular breast cancer (LBC). Carrying a pathogenic allele at this position predisposes individuals to high-penetrance cancer syndromes, although overall population frequency is exceptionally low.
What each genotype means
Typical CDH1 profile
This genotype represents the common, non-pathogenic form of the CDH1 gene. Individuals with this profile do not carry the specific pathogenic variant associated with hereditary diffuse gastric cancer and lobular breast cancer syndrome.
This is the most common genotype found in the general population.
Increased cancer risk carrier
This genotype indicates the presence of a pathogenic variant in the CDH1 gene, which is associated with an increased lifetime risk for hereditary diffuse gastric cancer and lobular breast cancer. Because this is a hereditary predisposition, individuals with this result should consult with a genetic counselor or oncologist to discuss appropriate clinical surveillance and risk management strategies.
This specific variant is extremely rare, with a global frequency of less than 0.00001 in the general population.
High cancer risk carrier
This genotype indicates the presence of the pathogenic variant on both copies of the CDH1 gene. This status is associated with a significantly elevated lifetime risk for hereditary diffuse gastric cancer and lobular breast cancer, and requires professional medical evaluation and specialized clinical management.
This homozygous genotype is exceptionally rare and is not typically observed in the general population.
Genomic Context and the CDH1 Gene
The rs121912577 variant represents a single nucleotide alteration located within the CDH1 gene on chromosome 16q22.1. The CDH1 gene encodes epithelial cadherin, commonly referred to as E-cadherin, a crucial transmembrane glycoprotein. E-cadherin plays a vital role in maintaining calcium-dependent cell-cell adhesion, stabilizing epithelial architecture, and regulating intracellular signaling cascades via its interactions with catenins. Because proper cellular adhesion suppresses abnormal cellular mobility and invasion, CDH1 functions primarily as a classical tumor suppressor gene. Disruptions in the CDH1 sequence can destabilize the protein structure, impair adhesion complexes, and contribute to unregulated cell growth, especially in glandular tissues.
Associated Health Predispositions: HDGC and LBC
Pathogenic variants in CDH1, such as rs121912577, are recognized as primary genetic drivers of Hereditary Diffuse Gastric Cancer (HDGC) and hereditary lobular breast cancer (HLBC), according to consensus guidelines by the [International Gastric Cancer Linkage Consortium](https://pmc.ncbi.nlm.nih.gov/articles/PMC7116190). Unlike intestinal-type stomach cancers, diffuse gastric cancer does not form a discrete exophytic mass; instead, malignant signet-ring cells infiltrate widely throughout the stomach wall. For women harboring pathogenic CDH1 alterations, there is also a substantially heightened lifetime risk of developing invasive lobular breast cancer. Because the clinical penetrance is elevated, individuals carrying true pathogenic variants are monitored closely for syndromic manifestations.
Strength of Clinical Evidence and Classification
While major truncating mutations in CDH1 have definitive clinical classifications, specific single-nucleotide variants may hold limited or evolving evidence depending on functional validation. Variant curation panels, adhering to standards from the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen), require strict criteria to distinguish benign missense variation from true loss-of-function lesions. In historical cohorts, research has demonstrated that germline CDH1 pathogenic mutations strongly correlate with early-onset diffuse stomach malignancies. However, population genomic databases like gnomAD occasionally identify unselected carriers without personal or familial tumor history, demonstrating that penetrance estimates continue to be refined by modern research cohorts.
Population Frequency and Allele Distribution
Across broad global populations, pathogenic CDH1 variants are extraordinarily rare. According to large-scale sequencing initiatives such as the Genome Aggregation Database (gnomAD), the global minor allele frequency (MAF) for rs121912577 is below 0.00001, meaning it is virtually absent from general healthy reference cohorts. When identified, it is almost exclusively seen in the heterozygous state (a single altered allele) within families meeting syndromic criteria for hereditary cancer or during targeted hereditary cancer gene panels. The vast majority of the human population carries the standard wild-type genotype, maintaining fully functional E-cadherin production across epithelial tissues.
Navigating Genetic Results and Clinical Management
Direct-to-consumer or exploratory sequencing identifying a flagged variant in CDH1 should be viewed cautiously. Research findings must always be confirmed through certified, diagnostic-grade clinical genetic testing before taking any clinical actions. For confirmed carriers of pathogenic CDH1 alterations, expert clinical management guidelines outlined in medical consensus reviews recommend specialized pathways, which may include enhanced endoscopic surveillance, risk-reducing gastrectomy discussions, and annual breast MRI screening starting in early adulthood. Genetic testing results provide probabilistic risk assessments rather than a definitive diagnosis of cancer, and all care decisions require guidance from a board-certified genetic counselor or oncology specialist.
How common is this variant?
The rs121912577 variant is exceptionally rare across all surveyed global populations, with an estimated gnomAD minor allele frequency (MAF) of less than 0.00001.
Frequently asked questions
What does a CDH1 genetic mutation mean for cancer risk?
A pathogenic variant in the CDH1 gene impairs the tumor-suppressing protein E-cadherin, leading to an increased lifetime risk of developing hereditary diffuse gastric cancer and lobular breast cancer. It does not mean an individual currently has cancer or will definitely develop it, but it indicates a strong predisposition that warrants high-risk medical screening.
Does having rs121912577 mean I have stomach cancer?
No, having a variant at rs121912577 is not a cancer diagnosis. It represents an inherited susceptibility factor. Any raw genetic finding must be verified in a clinical laboratory, after which a medical team evaluates personal and family health history to determine appropriate screening.
How common is this variant in healthy individuals?
This variant is virtually absent from the general population, with a global frequency below 0.00001 in databases like gnomAD. Almost everyone carries two functional, standard copies of the CDH1 gene at this location.
What medical screening is typically recommended for CDH1 carriers?
Established clinical guidelines often recommend specialized annual endoscopic surveillance with targeted biopsies and consultation regarding risk-reducing total gastrectomy. For female carriers, annual breast screening with breast MRI is generally recommended starting around age 30.
Sources & further reading
Educational information only, last refreshed 9/5/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121912577?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29